These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31551296)

  • 1. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
    Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
    McFall T; Schomburg NK; Rossman KL; Stites EC
    Cell Commun Signal; 2020 Nov; 18(1):179. PubMed ID: 33153459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
    Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
    J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
    Rabara D; Tran TH; Dharmaiah S; Stephens RM; McCormick F; Simanshu DK; Holderfield M
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22122-22131. PubMed ID: 31611389
    [No Abstract]   [Full Text] [Related]  

  • 7. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 9. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.
    Stites EC
    Methods Mol Biol; 2021; 2262():311-321. PubMed ID: 33977486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
    BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
    BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.
    McFall T; Stites EC
    Cell Rep; 2021 Dec; 37(11):110096. PubMed ID: 34910921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.